GORDAGEN CONFIRMS BIOAVAILABILITY IN PHASE I STUDY FOR EVIDENCE-BASED NUTRACEUTICALS

MELBOURNE, Australia, Sept. 9, 2015 / Medianet International-AsiaNet/ -- - Primary endpoints of Phase I Single Ascending Dose pharmacokinetic study achieved - Bioavailability of Gordagen’s MELT3(TM) formulation confirmed, with good plasma levels obtained - Dose relationship of MELT3(TM) demonstrated, along with significant duration in plasma - MELT3(TM) tablets confirmed to be easy to take, palatable and well tolerated Gordagen Pharmaceuticals, a privately-held company commercializing evidence-based nutraceuticals and pharmaceuticals, today announced results for the first part of its Phase I clinical trial, a Single Ascending Dose Pharmacokinetics (PK) study, with the Company preparing results for publication.  The study assessed the Company’s “melt-then-swallow” technology (MELT3(TM)), which is a formulation based on annatto-derived tocotrienols.    http://mrem.bernama.com/viewsm.php?idm=25223